An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells

BACKGROUND: Acquired drug resistance to irinotecan is one of the significant obstacles in the treatment of advanced gastric cancer. This study was performed to clarify the effect of epidermal growth factor receptor (EGFR) inhibitors in combination with SN38, an active metabolite of irinotecan, on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yashiro, M, Qiu, H, Hasegawa, T, Zhang, X, Matsuzaki, T, Hirakawa, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242520/
https://www.ncbi.nlm.nih.gov/pubmed/21997136
http://dx.doi.org/10.1038/bjc.2011.397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242520/
https://www.ncbi.nlm.nih.gov/pubmed/21997136
http://dx.doi.org/10.1038/bjc.2011.397

Ejemplares similares